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M.D. would like to dedicate this work to the late Peter Ekblom (1952–2005).Abstract Transgenically introduced laminin (LN) a1 chain pre-
vents muscular dystrophy in LNa2 chain deﬁcient mice. We now
report increased integrin a7Bb1D synthesis in dystrophic LNa2
chain deﬁcient muscle. Yet, immunoﬂuorescence demonstrated a
reduced expression of integrin a7B subunit at the sarcolemma.
Transgenic expression of LNa1 chain reconstituted integrin
a7B at the sarcolemma. Expression of a- and b-dystroglycan is
enhanced in LNa2 chain deﬁcient muscle and normalized by
transgenic expression of LNa1 chain. We suggest that LNa1
chain in part ameliorates the development of LNa2 chain deﬁ-
cient muscular dystrophy by retaining the binding sites for inte-
grin a7Bb1D and a-dystroglycan, respectively.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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dystrophy1. Introduction
Laminins (LN) are large heterotrimeric glycoproteins com-
posed of one a, one b and one c chain [1]. The main LNa chain
in muscle is LNa2 chain and mutations in the gene encoding
this chain lead to LNa2 chain deﬁcient congenital muscular
dystrophy,MDC1A [2]. This disorder is characterized by severe
muscle weakness, hypotonia and joint contractures with onset
at birth or in young infancy [3]. Mouse models for the disease
have been used by us and others to test novel therapeutic ap-
proaches for MDC1A [4–9]. We recently demonstrated that
LNa1 chain signiﬁcantly reduces muscular dystrophy [7] and
restores fertility in LNa2 chain deﬁcient dy3K/dy3K mice [9].
LNa2 chain is associated with muscle ﬁbers by at least two
distinct protein complexes; integrin a7b1 and dystroglycan
[10,11]. Integrin subunits a7B and b1D are the major isoforms
in skeletal muscle [12,13] and the importance of integrin a7
subunit in muscle is underscored by the fact that absence of
integrin a7 in man and mouse causes muscular dystrophy
[14,15]. Dystroglycan is a central element of the dystrophin-*Corresponding author. Fax: +46 46 222 08 55.
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doi:10.1016/j.febslet.2006.02.027glycoprotein complex (DGC) and is composed of the a and
b subunits, which are derived from a single gene by posttrans-
lational cleavage [16]. a-Dystroglycan is an extracellular
peripheral membrane protein that binds to LNa2 chain and
b-dystroglycan is the transmembrane moiety that anchors a-
dystroglycan to the sarcolemma [17]. Also, dystroglycan is cru-
cial for normal muscle function as mice lacking dystroglycan in
muscle, and humans and mice with hypoglycosylated a-dystro-
glycan develop muscular dystrophy [18–21]. LNa1 chain also
binds integrin a7b1 and a-dystroglycan [22,23]. However, it re-
mains to be determined if LNa1 chain mediated rescue of
LNa2 chain deﬁcient muscular dystrophy involves integrin
a7b1 and dystroglycan. Here, we show that transgenic expres-
sion of LNa1 chain restores normal localization of integrin
a7B subunit and normalizes dystroglycan expression in mus-
cle. We conclude that LNa1 chain mediated correction of
LNa2 chain deﬁcient muscular dystrophy engages integrin
a7Bb1D and dystroglycan.2. Materials and methods
2.1. Transgenic animals
Dy3K/dy3K and dy3KLNa1TG mice were previously described [4,7,9].
Animals were maintained in the BMC animal facilities according to
animal care guidelines.2.2. Quantitative real time PCR
Total RNA was isolated independently from skeletal and cardiac
muscles of three wild-type, three dy3K/dy3K and three dy3KLNa1TG
mice using TRIzol reagent (Invitrogen). First-strand cDNA synthesis
and quantitative real time PCR was carried out as previously described




integrin b1D, Fw-gTggAgACTCCAgACTgTCCTACT, Rev-AACT-
CAgAgACCAgCTTTACgTC, ﬂuorescein-TCAAATTTAgCAAATT-
CCCTTCTgTCATgAA and LC-Red-640-TATCATTAAAAgTTTC-
CAAATCAgCAgCAAgg; for dystroglycan, Fw-AgggACTggAA-
gAACCAgCTT, Rev-TATgACTgTgTgggTCCCAgTgTA, ﬂuorescein-
CCCgACAACAgCCgTACCgTC and LC-Red-640-ggAATgCCAAC-
CACggTgggA; for GAPDH, Fw-TTgTCAgCAATg CATCCTgC,
Rev-CCgTTCAgCTCTgggATgAC, ﬂuorescein-CACCCAgAAgAC-
TgTggATggCCCCT and LC-Red-640-TggAAAgCTgTggCgTgATgg-
CCg. PCR was repeated one to three times per extraction. Statistical
signiﬁcance was examined by using Student’s t-test.blished by Elsevier B.V. All rights reserved.
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Proteins were extracted from 150 mg skeletal muscle powder of two
wild-type, two dy3K/dy3K and two dy3KLNa1TG mice in 1% NP-40 in
50 mM Tris–HCl, pH 7.4; 2 mM PMSF, 1 mM CaCl2, 1 mM MgCl2
and 1:25 dilution of Protease Cocktail (Complete EDTA-free, Roche).
Two independent extractions were performed. Protein concentration
was determined by using BCA assay (Pierce).
Membrane proteins were isolated by using ProteoExtract Native
Membrane Protein Extraction Kit (Calbiochem) according to the man-
ufacturer’s instructions. Two independent extractions from muscles
of two wild-type, two dy3K/dy3K and two dy3KLNa1TG mice were
performed.
Dystroglycan enriched samples were independently extracted from
150 mg skeletal muscle powder of three wild-type, four dy3K/dy3K
and three dy3KLNa1TG mice in 1· TBS buﬀer containing 1% Triton
X-100 and 1:25 dilution of Protease Cocktail (Complete EDTA-free,
Roche) as previously described [21]. One to two extractions were per-
formed per each set of animals. Protein concentration was determined
by using DC assay (BioRad).
2.4. Western blot
Integrin and dystroglycan protein containing muscle samples,
respectively, were separated on 7.5% polyacrylamide–SDS gels, blotted
and hybridized as previously described [9]. The following primary anti-
bodies were used: rabbit polyclonal antibodies against integrin a7B
subunit [24], integrin b1D subunit [25], and b-dystroglycan [7] and
mouse monoclonal antibody IIH6C4 against a-dystroglycan (Upstate).
Experiments were repeated 1–4 times per protein extraction. Quantiﬁ-
cation of chemiluminescence signals was performed using a CCD cam-
era (LAS 1000, Fujiﬁlm) and the software program Image Gauge V4
(Fujiﬁlm). Statistical signiﬁcance was examined by using paired t-test.
2.5. Immunostaining
Immunoﬂuorescence was performed as previously described [7,9].
Skeletal and cardiac muscles were collected and analyzed from three
mice of each genotype. Sections were incubated with the same antibod-
ies used in Western blot analyses except for the integrin b1D stainings,
for which we used the mouse monoclonal antibody 2B1 [13]. For inte-
grin b1D stainings we used the VECTOR M.O.M. Immunodetection
kit (Vector Laboratories) according to the manufacturer’s instructions.3. Results
3.1. Integrin a7Bb1D analyses
Quantitative real time PCR on cDNA obtained from total
muscle RNA of 3–4-month-old wild-type, 4-week-old dy3K/
dy3K and 3–4-month-old rescued (dy3KLNa1TG) mice demon-
strated an approximately 2.4-fold upregulation of integrin a7B
mRNA and about 2.7-fold increase in b1D mRNA expression
in muscles of dy3K/dy3K mice. A 2.6- and 2.9-fold increase in
a7B and b1D mRNA expression, respectively, was noted in
muscles of dy3KLNa1TG animals (Table 1).Table 1
Relative amounts of integrin a7B and b1D mRNAs in wild-type, dy3K/
dy3K and dy3KLNa1TG skeletal muscle
a7B b1D
WT 1.09 ± 0.22 5.27 ± 1.03
dy3K/dy3K 2.67 ± 0.57 (P < 0.02) 14.20 ± 3.71 (P < 0.03)
dy3KLNa1TG 2.85 ± 0.81 (P < 0.034) 15.15 ± 4.04 (P < 0.03)
Quantitative RT-PCR with sequence-speciﬁc hybridization probes was
performed. Integrin levels were normalized to GAPDH and expressed
as relative mRNA amounts and are shown as mean values ± S.E.M.
(n = 4–5). Signiﬁcantly more integrin a7B and b1D mRNAs were seen
in dy3K/dy3K and dy3KLNa1TG skeletal muscle compared with wild-
type muscle. No signiﬁcant diﬀerence was seen between dy3K/dy3K and
dy3KLNa1TG skeletal muscle.To analyze whether mRNA levels of integrin a7Bb1D corre-
lated with protein expression we performed Western blot anal-
yses on muscle protein extracts from wild-type, dy3K/dy3K and
dy3KLNa1TG animals. Consistently with the mRNA data,
immunoblotting experiments showed an approximately 1.5-
fold upregulation of integrin a7B in dystrophic muscle and
an approximately 1.4-fold upregulation in rescued muscle.
Integrin b1D was upregulated about 4.8-fold in dystrophic
muscle and about 4.5-fold in rescued muscles (Fig. 1). We also
studied membrane enriched fractions (internal and cell surface
membranes) from muscles of wild-type, dy3K/dy3K and dy3KL-
Na1TG animals. Also this assay showed an upregulation of
a7B (1.4-fold) and b1D (4–7-fold) integrin subunits,
respectively, in both dystrophic and rescued muscles (Fig. 1
and data not shown).
By immunoﬂuorescence we studied the distribution of inte-
grin a7B subunit in diﬀerent muscles from 4-month-old wild-
type, 4-week-old dy3K/dy3K and 4-month-old dy3KLNa1TG
mice. Surprisingly, muscle cryosections prepared from dy3K/
dy3K mice exhibited a severe reduction in sarcolemmal staining
of integrin a7B subunit. Downregulation was most evident in
quadriceps, triceps brachii, tibialis anterior and gluteus maxi-
mus but to a lesser extent in diaphragm (Fig. 2 and data not
shown). The receptor was normally expressed in blood vessels,
and staining was also maintained in myotendinous junctions
(Fig. 2). Notably, in dy3KLNa1TG mice the expression of inte-
grin a7B subunit was restored at the sarcolemma of all exam-
ined muscles (Fig. 2 and data not shown).
Immunoﬂuorescence revealed that expression of b1D inte-
grin did not appear to be altered in dy3K/dy3K or dy3KLNa1TG
muscles as compared with wild-type muscles (Fig. 2).
Integrin a7B chain is also highly expressed in cardiac muscle
[13] and to analyze whether absence of LNa2 chain leads to re-
duced integrin a7B expression at the heart sarcolemma we ana-
lyzed cardiac muscles from wild-type, dy3K/dy3K and
dy3KLNa1TG mice by immunoﬂuorescence. Indeed, lack of
LNa2 chain led to reduced levels of integrin a7B subunit in
sarcolemma of dy3K/dy3K hearts. Transgenic expression of
LNa1 chain restored integrin a7B expression (Fig. 3). Unlike
skeletal muscle, however, no increase in integrin a7 mRNA
expression was noted in dy3K/dy3K or dy3KLNa1TG cardiac
muscle (Table 2).
3.2. Dystroglycan analyses
To analyze whether absence of LNa2 chain alters dystrogly-
can expression in dy3K/dy3K muscle we performed quantitative
RT-PCR on cDNA obtained from total muscle RNA of 3–4-
month-old wild-type, 4-week-old dy3K/dy3K and 3–4-month-
old dy3KLNa1TG mice. This assay revealed an approximately
2.1-fold upregulation of dystroglycan mRNA in muscles of
dy3K/dy3K mice, but no signiﬁcant diﬀerence in dystroglycan
mRNA expression between dy3KLNa1TG and wild-type mus-
cles (Table 3).
Western blot analysis demonstrated that both a- and b-dys-
troglycan were upregulated in dy3K/dy3K mice (about 1.7- and
2.0-fold, respectively). Notably, in muscles of animals rescued
by the LNa1 chain transgene, expression of dystroglycans was
normalized (Fig. 4).
By immunoﬂuorescence, we assessed the expression of dys-
troglycans in muscles from 4-month-old wild-type, 4-week-
old dy3K/dy3K and 4-month-old dy3KLNa1TG mice. a- and
b-Dystroglycan were clearly present in sarcolemma of all
Fig. 1. Upregulation of integrin a7B and b1D subunits in dy3K/dy3K and dy3KLNa1TG skeletal muscle. (A) Immunoblotting of total protein lysates
from wild-type (WT), dy3K/dy3K and dy3KLNa1TG skeletal muscles. (B) Immunoblotting of membrane fractions puriﬁed from WT, dy3K/dy3K and
dy3KLNa1TG skeletal muscles. Proteins were separated under non-reducing conditions. Coomassie blue-stained loading control is shown in the lower
panel of each blot. (C) Quantitative measurements of integrin a7Bb1D expression in dy3K/dy3K and dy3KLNa1TG muscle (from blots shown in A).
Results are expressed relative to wild-type and are shown as means ± S.E.M. (n = 5–6). **, signiﬁcantly diﬀerent from wild-type (P < 0.002).
*, signiﬁcantly diﬀerent from wild-type (P < 0.03).
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rior, gluteus maximus and diaphragm) both in dy3K/dy3K and
dy3KLNa1TG mice (Fig. 5 and data not shown). The enhance-
ment in expression of dystroglycans in dystrophic muscles as
shown by Western blot analyses might not be detected by
immunoﬂuorescence, thus the staining in muscles of all ani-
mals appeared similar.4. Discussion
Previous reports have shown abolished expression of inte-
grin a7 subunit at the sarcolemma of LNa2 chain deﬁcient
muscle [24,26,27]. In agreement with these studies, we show
loss of integrin a7B at the sarcolemma of dy3K/dy3K muscles
by immunoﬂuorescence. However, we noted increased a7B
synthesis in dy3K/dy3K muscles. Thus, integrin a7B is produced
in excess but may be mislocated inside the cell in the absence ofLNa2 chain. Another possibility is that in the absence of li-
gand, integrin a7B subunit can not be retained at the cell sur-
face. It should be noted that membrane preparations are
enriched in both internal and cell surface membranes and cell
surface membranes only constitute a minor portion of all
membranes. This could explain that absence of integrin a7
subunit at the cell surface is not detected in this assay. Never-
theless, integrin a7B expression was restored at the sarco-
lemma upon transgenic expression of LNa1 chain in skeletal
and cardiac muscles.
Dystroglycan is also regulated by absence of LNa2 chain.
Unexpectedly, we found that lack of LNa2 subunit leads to en-
hanced expression of a-dystroglycan in dy3K/dy3K muscles. The
increased level of a-dystroglycan expression is accompanied by
upregulation of b-dystroglycan. It was previously demon-
strated that the amount of a-dystroglycan was decreased
whereas that of b-dystroglycan was increased in dyW/dyW mice,
suggesting a diﬀerent regulation mechanism for both subunits
Fig. 2. Integrin a7B expression is restored at the sarcolemma upon transgenic expression of LNa1 chain. Cross-sections of quadriceps femoris
(Quad) and tibialis anterior (TA) from WT, dy3K/dy3K and dy3KLNa1TG mice were stained with antibodies against integrin a7B subunit. Quad
magn. represents a higher magniﬁcation micrograph of quadriceps femoris. Integrin a7B staining in blood vessels and at the myotendinous junction
(MTJ) remains unchanged in dy3K/dy3K muscle. Expression of b1D integrin appears normal in muscles of all genotypes. Bar, 30 lm.
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regulatory phenomenon for a- and b-dystroglycan in dy3K/
dy3K muscles. Moreover, in contrast to Bentzinger et al. [28]Fig. 3. Integrin a7B expression is normalized in cardiac muscle upon transg
WT, dy3K/dy3K and dy3KLNa1TG mice were stained with antibodies againstwe were not able to detect a reduction of a-dystroglycan in
dy3K/dy3Kmuscle. The diﬀerent observations might be due
to the use of diﬀerent antibodies. We used the monoclonalenic expression of LNa1 chain. Cross-sections of cardiac muscle from
LNa1 chain, LNa2 chain and integrin a7B. Bar, 50 lm.
Table 3
Relative amounts of dystroglycan mRNA in wild-type, dy3K/dy3K and
dy3KLNa1TG skeletal muscle
WT 2.14 ± 0.37
dy3K/dy3K 4.54 ± 0.83 (P < 0.03)
dy3KLNa1TG 3.15 ± 0.70
Quantitative RT-PCR with sequence-speciﬁc hybridization probes was
performed. Dystroglycan levels were normalized to GAPDH and ex-
pressed as relative mRNA amounts and are shown as mean val-
ues ± S.E.M. (n = 5). Signiﬁcantly more dystroglycan mRNA was seen
in dy3K/dy3K muscle compared with wild-type muscle (P < 0.03). No
signiﬁcant diﬀerence was noted between wild-type and dy3KLNa1TG
skeletal muscle.
Table 2
Relative amounts of integrin a7B mRNA in wild-type, dy3K/dy3K and
dy3KLNa1TG cardiac muscle
WT 1.27 ± 0.38
dy3K/dy3K 1.25 ± 0.32
dy3KLNa1TG 1.84 ± 0.70
Quantitative RT-PCR with sequence-speciﬁc hybridization probes was
performed. Integrin a7B levels were normalized to GAPDH and ex-
pressed as relative mRNA amounts and are shown as mean val-
ues ± S.E.M. (n = 5). Expression levels did not diﬀer signiﬁcantly from
each other.
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whereas Bentzinger et al. [28] used an antibody directed
against the core protein of a-dystroglycan and further studies
are needed to clarify this discrepancy.Fig. 4. Expression of a- and b-dystroglycan is upregulated in dy3K/dy3K
preparations from muscles of WT, dy3K/dy3K and dy3KLNa1TG mice were an
and b-dystroglycan. Coomassie blue-stained loading control is shown in the
dystroglycan expression in dy3K/dy3K and dy3KLNa1TG muscle, respectiv
means ± S.E.M. (n = 8–9). **, Signiﬁcantly diﬀerent from wild-type (P < 0.0
diﬀerence was noted between wild-type and dy3KLNa1TG skeletal muscle.It remains unclear how the 2-fold upregulation of dystrogly-
cans can be implicated in the muscle pathology of LNa2 chain
deﬁcient mice. Mice overexpressing dystroglycan do not dis-
play any overt phenotype [29 and our unpublished data] and
obviously the increase in dystroglycan expression is of no
apparent help. Hence, normalization of dystroglycan expres-
sion in LNa2 chain deﬁcient mice harbouring the LNa1 trans-
gene might not be crucial for normal muscle function,
although we cannot exclude that it is beneﬁcial.
Whether either integrin a7b1 or dystroglycan is the de facto
crucial receptor for LNa2 chain in muscle is not easily an-
swered. A functional redundancy between integrin a7b1 and
the DGC in the maintenance of muscle membrane integrity
has been suggested [12]. Upregulation of integrin a7b1 has
been observed in patients and mice lacking dystrophin as well
as in mice deﬁcient in c- and d-sarcoglycan [12,30]. Also, trans-
genic overexpression of integrin a7BX2 reduced the dystrophic
phenotype in mice lacking both dystrophin and utrophin [30]
and double-mutant mice deﬁcient in c-sarcoglycan and inte-
grin a7 subunit exhibit profound muscle degeneration, arguing
in favour of complementary roles for both complexes [12].
Also, whether LNa1 chain mediated rescue of LNa2 chain
deﬁciency occurs mainly through a7b1 integrin, dystroglycan
or both remains to be tested. However, our results showing
that expression of both integrin a7b1 and dystroglycan are af-
fected by lack of LNa2 chain would support the view that
these receptors act in concert. Nevertheless, this could be
tested and further work in our laboratory is aimed at establish-
ing whether LNa1 chain lacking the integrin- and dystroglycanmuscle and normalized in dy3KLNa1TG muscle. (A) Glycoprotein
alyzed by SDS–PAGE and immunoblotting using antibodies against a-
lower panel of the blots. (B) Quantitative measurements of a- and b-
ely. Results are expressed relative to wild-type and are shown as
08). *, Signiﬁcantly diﬀerent from wild-type (P < 0.05). No signiﬁcant
Fig. 5. Expression of a- and b-dystroglycan in dy3K/dy3K and dy3KLNa1TG muscles. Cross-sections of quadriceps femoris (Quad) and tibialis
anterior (TA) from WT, dy3K/dy3K and dy3KLNa1TG mice were stained with antibodies against a- and b-dystroglycan. Quad magn. is a higher
magniﬁcation micrograph of quadriceps femoris. Expression of a- and b-dystroglycan appears normal in dy3K/dy3K and dy3KLNa1TG muscles. Bar,
30 lm.
1764 K.I. Gawlik et al. / FEBS Letters 580 (2006) 1759–1765binding sites, respectively, reduces LNa2 chain deﬁcient mus-
cular dystrophy.
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